Plasma fetuin‐A concentration, genetic variation in the AHSG gene and risk of colorectal cancer

Fetuin‐A, also referred to as α2‐Heremans‐Schmid glycoprotein (AHSG), is a liver protein known to inhibit insulin actions. Hyperinsulinemia is a possible risk factor for colorectal cancer; however, the role of fetuin‐A in the development of colorectal cancer is unclear. We investigated the associati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2015-08, Vol.137 (4), p.911-920
Hauptverfasser: Nimptsch, Katharina, Aleksandrova, Krasimira, Boeing, Heiner, Janke, Jürgen, Lee, Young‐Ae, Jenab, Mazda, Kong, So Yeon, Tsilidis, Konstantinos K., Weiderpass, Elisabete, Bueno‐De‐Mesquita, H. B(as), Siersema, Peter D., Jansen, Eugène H.J.M., Trichopoulou, Antonia, Tjønneland, Anne, Olsen, Anja, Wu, Chunsen, Overvad, Kim, Boutron‐Ruault, Marie‐Christine, Racine, Antoine, Freisling, Heinz, Katzke, Verena, Kaaks, Rudolf, Lagiou, Pagona, Trichopoulos, Dimitrios, Severi, Gianluca, Naccarati, Alessio, Mattiello, Amalia, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Peeters, Petra H., Ljuslinder, Ingrid, Nyström, Hanna, Brändstedt, Jenny, Sánchez, María‐José, Gurrea, Aurelio Barricarte, Bonet, Catalina Bonet, Chirlaque, María‐Dolores, Dorronsoro, Miren, Quirós, José Ramón, Travis, Ruth C., Khaw, Kay‐Tee, Wareham, Nick, Riboli, Elio, Gunter, Marc J., Pischon, Tobias
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Fetuin‐A, also referred to as α2‐Heremans‐Schmid glycoprotein (AHSG), is a liver protein known to inhibit insulin actions. Hyperinsulinemia is a possible risk factor for colorectal cancer; however, the role of fetuin‐A in the development of colorectal cancer is unclear. We investigated the association between circulating fetuin‐A and colorectal cancer risk in a nested case–control study within the European Prospective Investigation into Cancer and Nutrition. Fetuin‐A concentrations were measured in prediagnostic plasma samples from 1,367 colorectal cancer cases and 1,367 matched controls. In conditional logistic regression models adjusted for potential confounders, the estimated relative risk (95% confidence interval) of colorectal cancer per 40 µg/mL higher fetuin‐A concentrations (approximately one standard deviation) was 1.13 (1.02–1.24) overall, 1.21 (1.05–1.39) in men, 1.06 (0.93–1.22) in women, 1.13 (1.00–1.27) for colon cancer and 1.12 (0.94–1.32) for rectal cancer. To improve causal inference in a Mendelian Randomization approach, five tagging single nucleotide polymorphisms of the AHSG gene were genotyped in a subset of 456 case–control pairs. The AHSG allele‐score explained 21% of the interindividual variation in plasma fetuin‐A concentrations. In instrumental variable analysis, genetically raised fetuin‐A was not associated with colorectal cancer risk (relative risk per 40 µg/mL genetically determined higher fetuin‐A was 0.98, 95% confidence interval: 0.73–1.33). The findings of our study indicate a modest linear association between fetuin‐A concentrations and risk of colorectal cancer but suggest that fetuin‐A may not be causally related to colorectal cancer development. What's new? Fetuin‐A is a liver protein associated with insulin resistance, but with no defined role yet in colorectal cancer. In this prospective study, the authors uncover a modest linear association between fetuin‐A levels and higher risk of colorectal cancer, but this was only observed in male participants. In addition, no association was observed between fetuin‐A variants and colorectal cancer risk in a Mendelian randomization analysis, arguing against a direct role of fetuin‐A in colorectal carcinogenesis.
ISSN:0020-7136
1097-0215
1097-0215
DOI:10.1002/ijc.29448